GlassScriptPhysician profile
Penny A Danna
NPI 1902897994
$2,635.89
in general payments reported to CMS, 2019-2025
32 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $321 · 2021: $324 · 2022: $236 · 2023: $288 · 2024: $207 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.03 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Therapeuticsmd, INC. | $239.31 | 2019-2022 | |
| Hologic Sales and Service, LLC | $215.13 | 2020-2025 | Aptima |
| Allergan, INC. | $147.32 | 2019-2020 | |
| Pfizer INC. | $147.23 | 2019-2024 | |
| Exeltis, USA INC. | $146.39 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $131.94 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $101.42 | 2019-2025 | |
| Medical Device Business Services, INC. | $100.14 | 2020 | |
| Gauss Surgical INC. | $99.87 | 2019 | |
| Vertical Pharmaceuticals, LLC | $89.22 | 2019 | |
| Mayne Pharma Commercial LLC | $84.49 | 2021-2025 | |
| Becton, Dickinson and Company | $77.65 | 2019 | |
| Organon LLC | $77.17 | 2022-2025 | Nexplanon |
| Myriad Women'S Health, INC. | $56.16 | 2023 | Myrisk |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.72 | 2019 | |
| Coopersurgical, INC. | $52.65 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Avion Pharmaceuticals | $50.30 | 2019 | |
| Millicent US INC | $43.15 | 2022 | |
| Biogen, INC. | $42.36 | 2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $40.24 | 2019-2021 | |
| Agile Therapeutics, INC. | $39.73 | 2021-2024 | Twirla |
| Evofem Biosciences, INC. | $38.29 | 2022-2023 | Phexxi |
| Amag Pharmaceuticals, INC. | $27.95 | 2019-2020 | |
| Duchesnay USA Incorporated | $26.13 | 2019 | |
| Scynexis, INC. | $21.77 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.69 | 2019 | |
| Shield Therapeutics INC | $16.24 | 2025 | |
| Medtronic, INC. | $14.64 | 2021 | |
| Merck Sharp & Dohme LLC | $13.75 | 2021 | |
| Myovant Sciences INC. | $11.91 | 2022 | |
| Ethicon US, LLC | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Danna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.